一种基于血液检测的诊断和预测HBV相关疾病的弹性方法

Gege Hou, Yunru Chen, Xiaojing Liu, Dong Zhang, Zhimin Geng, Shubin Si

工程（英文） ›› 2024, Vol. 32 ›› Issue (1) : 174-185.

PDF(1998 KB)
PDF(1998 KB)
工程（英文） ›› 2024, Vol. 32 ›› Issue (1) : 174-185. DOI: 10.1016/j.eng.2023.06.013
研究论文
Article

一种基于血液检测的诊断和预测HBV相关疾病的弹性方法

作者信息 +

A Resilience Approach for Diagnosing and Predicting HBV-Related Diseases Based on Blood Tests

Author information +
History +

摘要

乙肝病毒(HBV)感染威胁着全球公共卫生安全，是导致肝脏相关疾病发病率和死亡率的主要原因。HBV持续感染引起的肝脏疾病检查方法包括实验室检测、超声、CT、核磁共振和肝活检等，重复的检查和多次诊断可能导致患者每次就医都面临高额费用。因此，迫切需要建立一种经济有效的诊断方法简化乙肝相关疾病的医疗流程。基于临床血液检测，我们构建复杂网络模型并定义功能恢复力评价指标，可以帮助医生评估患者的肝脏状况。其次，通过结合网络模型和动力学，发现导致患者向肝硬化或肝癌转化的关键血液指标及其相应的阈值，为进一步研究疾病临界状态和预防疾病恶化提供思路。结果表明功能恢复力的诊断宏观平均精度为84.74%，而在没有影像或活检辅助的情况下医生凭经验诊断的宏观平均精度为55.64%。从经济角度，与一般诊断方法相比，功能恢复力可以为大多数中国患者每次就诊节省至少30美元，为大多数美国患者节省至少400美元。在全球范围内，每年将节省至少105亿美元。因此，功能恢复力可以全面评估患者的肝脏状况，减少影像学检查的次数，避免肝病诊断过程中医疗资源的浪费。

Abstract

Chronic hepatitis B virus (HBV) infection, which threatens global public health, is a major contributor to liver-related morbidity and mortality. Examinations for liver diseases related to chronic HBV infection—including laboratory tests, ultrasounds, computed tomography (CT), and liver biopsies—may take up medical resources, particularly since they overlap in most instances. Thus, there is an urgent need to establish an economical and effective diagnosis method in order to streamline the medical process for HBV-related diseases. Using complex network models constructed based on clinical blood tests, we provide such a method by defining the novel measure of functional resilience to assess patients’ liver conditions. By combining network models and dynamics, we discovered the pivotal items and their corresponding thresholds, which can guide further research on preventing disease deterioration in critical states of these diseases. The macro-averaged precision of our method, functional resilience, is 84.74%, whereas the macro-averaged precision of physicians’ experience without assistance from imaging or biopsy is 55.63%. From an economic perspective, our approach could save the equivalent of at least 30 USD per visit for most Chinese patients and at least 400 USD per visit for most US patients, compared with general diagnostic methods. Globally, this will add to savings of at least 10.5 billion USD annually. Our method can comprehensively evaluate the condition of patients’ livers and help avert the waste of medical resources during the diagnosis of liver disease by reducing excessive imaging exams.

关键词

HBV相关疾病 / 功能弹性 / 医疗资源利用率 / 关键状态 / 网络

Keywords

HBV-related diseases / Functional resilience / Improve medical resource utilization / Critical states / Network

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
Gege Hou, Yunru Chen, Xiaojing Liu. 一种基于血液检测的诊断和预测HBV相关疾病的弹性方法. Engineering. 2024, 32(1): 174-185 https://doi.org/10.1016/j.eng.2023.06.013

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序
[1]
W.M. Lee. Hepatitis B virus infection. N Engl J Med, 337 (24) ( 1997), pp. 1733-1745
[2]
A.E. Mitchell, H.M. Colvin. Hepatitis and liver cancer:a national strategy for prevention and control of hepatitis B and C. National Academies Press, Washington, DC ( 2010)
[3]
D. Lavanchy. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 11 (2) ( 2004), pp. 97-107
[4]
N. Qirbi, A. Hall. Epidemiology of hepatitis B virus infection in the Middle East. EMHJ-Eastern Mediterranean Health J, 7 (6) ( 2001), pp. 1034-1045
[5]
Z. Kavosi, F. Zare, A. Jafari, M.R. Fattahi. Economic burden of hepatitis B virus infection in different stages of disease; a report from southern Iran. Middle East J Dig Dis, 6 (3) ( 2014), pp. 156-161
[6]
X. Li, J. Lu, S. Hu, K.K. Cheng, J. De Maeseneer, Q. Meng, et al.. The primary health-care system in China. Lancet, 390 (10112) ( 2017), pp. 2584-2594
[7]
Q. Liu, B. Wang, Y. Kong, K.K. Cheng. China’s primary health-care reform. Lancet, 377 (9783) ( 2011), pp. 2064-2066
[8]
WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. World Health Organization, Geneva ( 2015) [Report]
[9]
Y. Shimakawa, R. Njie, G. Ndow, M. Vray, P.S. Mbaye, P. Bonnard, et al.. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. J Hepatol, 69 (4) ( 2018), pp. 776-784
[10]
J. Bruix, M. Sherman. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology, 53 (3) ( 2011), pp. 1020-1022
[11]
T. Ichikawa, K. Saito, N. Yoshioka, A. Tanimoto, T. Gokan, Y. Takehara, et al.. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol, 45 (3) ( 2010), pp. 133-141
[12]
D. Ginzberg, R.J. Wong, R. Gish. Global HBV burden: guesstimates and facts. Hep Intl, 12 (4) ( 2018), pp. 315-329
[13]
A.K.M. Sazzadur Rahman, F.M. Javed Mehedi Shamrat, Z. Tasnim, J. Roy, S.A. Hossain. A comparative study on liver disease prediction using supervised machine learning algorithms. Int J Sci Tech Res, 8 (11) ( 2019), pp. 419-422
[14]
M. Owjimehr, H. Danyali, M.S. Helfroush, A. Shakibafard. Staging of fatty liver diseases based on hierarchical classification and feature fusion for back-scan-converted ultrasound images. Ultrason Imaging, 39 (2) ( 2017), pp. 79-95
[15]
S. Khan, R. Ullah, A. Khan, R. Ashraf, H. Ali, M. Bilal, et al.. Analysis of hepatitis B virus infection in blood sera using Raman spectroscopy and machine learning. Photodiagn Photodyn Ther, 23 ( 2018), pp. 89-93
[16]
K. Wang, X. Lu, H. Zhou, Y. Gao, J. Zheng, M. Tong, et al.. Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut, 68 (4) ( 2019), pp. 729-741
[17]
Q. Ye, L. Qin, M. Forgues, P. He, J.W. Kim, A. Peng, et al.. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 9 (4) ( 2003), pp. 416-423
[18]
G.L. Wong, V.W. Hui, Q. Tan, J. Xu, H.W. Lee, T.C. Yip, et al.. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. JHEP Rep, 4 (3) ( 2022), Article 100441
[19]
T.T. Chang, C.L. Lai, S.K. Yoon, S.S. Lee, H.S.M. Coelho, F.J. Carrilho, et al.. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 51 (2) ( 2010), pp. 422-430
[20]
P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, I.M. Jacobson, et al.. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 381 (9865) ( 2013), pp. 468-475
[21]
C.L. Lai, D. Wong, P. Ip, M. Kopaniszen, W.K. Seto, J. Fung, et al.. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol, 66 (2) ( 2017), pp. 275-281
[22]
G.L. Wong, H.L. Chan, C.W. Mak, S.K. Lee, Z.M. Ip, A.T. Lam, et al.. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology, 58 (5) ( 2013), pp. 1537-1547
[23]
C.Y. Wu, J.T. Lin, H.J. Ho, C.W. Su, T.Y. Lee, S.Y. Wang, et al.. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology, 147 (1) ( 2014), pp. 143-151
[24]
J.H. Shim, H.C. Lee, K.M. Kim, Y.S. Lim, Y.H. Chung, Y.S. Lee, et al.. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol, 52 (2) ( 2010), pp. 176-182
[25]
C.Y. Wu, Y.J. Chen, H.J. Ho, Y.C. Hsu, K.N. Kuo, M.S. Wu, et al.. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. J Am Med Assoc, 308 (18) ( 2012), pp. 1906-1913
[26]
C.M. Chu, C.C. Lin, Y.C. Chen, W.J. Jeng, S.M. Lin, Y.F. Liaw. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer, 107 (12) ( 2012), pp. 2010-2015
[27]
B. Yang, M. Li, W. Tang, W. Liu, S. Zhang, L. Chen, et al.. Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. Nat Commun, 9 ( 2018), p. 678
[28]
Y.S. White, P.J. Johnson, F. Davison, R. Williams. Frequency of hepatic HBV-DNA in patients with cirrhosis and hepatocellular carcinoma: relation to serum HBV markers. Br J Cancer, 61 (6) ( 1990), pp. 909-912
[29]
C. Neuveut, Y. Wei, M.A. Buendia. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol, 52 (4) ( 2010), pp. 594-604
[30]
B. Artegiani, L. van Voorthuijsen, R.G.H. Lindeboom, D. Seinstra, I. Heo, P. Tapia, et al.. Probing the tumor suppressor function of bap 1 in crispr-engineered human liver organoids. Cell Stem Cell, 24 (6) ( 2019), pp. 927-943
[31]
J.K. DiStefano, B. Davis. Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma. Cancers, 11 (4) ( 2019), p. 486
[32]
N.A. Terrault, A.S.F. Lok, B.J. McMahon, K.M. Chang, J.P. Hwang, M.M. Jonas, et al.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 67 (4) ( 2018), pp. 1560-1599
[33]
J.A. Marrero, L.M. Kulik, C.B. Sirlin, A.X. Zhu, R.S. Finn, M.M. Abecassis, et al.. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology, 68 (2) ( 2018), pp. 723-750
[34]
J.K. Heimbach, L.M. Kulik, R.S. Finn, C.B. Sirlin, M.M. Abecassis, L.R. Roberts, et al.. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 67 (1) ( 2018), pp. 358-380
[35]
C.G. Child, J.G. Turcotte. Surgery and portal hypertension. Major Probl Clin Surg, 1 ( 1964), pp. 1-85
[36]
R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, R. Williams. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg, 60 (8) ( 1973), pp. 646-649
[37]
W.S. McCulloch, W. Pitts. A logical calculus of the ideas immanent in nervous activity. Bull Math Biophys, 5 (4) ( 1943), pp. 115-133
[38]
H. Sompolinsky, A. Crisanti, H.J. Sommers. Chaos in random neural networks. Phys Rev Lett, 61 (3) ( 1988), pp. 259-262
[39]
D.J. Amit. Modeling brain function: the world of attractor neural networks [dissertation]. Cambridge University, Cambridge ( 1989)
[40]
S. Shalapour, X.J. Lin, I.N. Bastian, J. Brain, A.D. Burt, A.A. Aksenov, et al.. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature, 551 (7680) ( 2017), pp. 340-345
[41]
J. Wu, M. Barahona, Y. Tan, H. Deng. Natural connectivity of complex networks. Chin Phys Lett, 71 (7) ( 2010), Article 078902
[42]
M. Rosvall, C.T. Bergstrom. An information-theoretic framework for resolving community structure in complex networks. PNAS, 104 (18) ( 2007), pp. 7327-7331
[43]
M. Rosvall, C.T. Bergstrom. Maps of random walks on complex networks reveal community structure. PNAS, 105 (4) ( 2008), pp. 1118-1123
[44]
B. Barzel, Y. Liu, A.L. Barabási.Constructing minimal models for complex system dynamics. Nat Commun, 6 (1) ( 2015), p. 7186
[45]
F. Baumann, P. Lorenz-Spreen, I.M. Sokolov, M. Starnini. Modeling echo chambers and polarization dynamics in social networks. Phys Rev Lett, 124 (4) ( 2020), Article 048301
[46]
N.A. Terrault, N.H. Bzowej, K.M. Chang, J.P. Hwang, M.M. Jonas, M.H. Murad. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 63 (1) ( 2016), pp. 261-283
[47]
S. Nagula, D. Jain, R.J. Groszmann, G. Garcia-Tsao. Histological-hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol, 44 (1) ( 2006), pp. 111-117
[48]
M. Kumar, P. Sakhuja, A. Kumar, N. Manglik, A. Choudhury, S. Hissar, et al.. Histological subclassification of cirrhosis based on histological-haemodynamic correlation. Aliment Pharmacol Ther, 27 (9) ( 2008), pp. 771-779
[49]
C. Zhao, W. Zhou, W. Chen, C. Zhang. Clinical significanceof afetoprotein ininitial diagnosis of primary hepatic cancer. J Clin Hepatol, 29 (9) ( 2013), pp. 698-701
PDF(1998 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉